Masking epistasis between MYC and TGF-β pathways in antiangiogenesis-mediated colon cancer suppression

Journal of the National Cancer Institute

Volumn 106, Issue 4, 2014, Pages

  Dews, Michael ^a   Tan, Grace S ^a   Hultine, Stacy ^a   Raman, Pichai ^b   Choi, Jaewoo ^c   Duperret, Elizabeth K ^c   Lawler, Jack ^d   Bass, Adam ^d   Thomas Tikhonenko, Andrei ^a,c,e  

^a Mammalian Neurogenetics Group   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e 3012 Colket Translational Research Bldg   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; K RAS PROTEIN; MYC PROTEIN; SHORT HAIRPIN RNA; SMAD4 PROTEIN; TAMOXIFEN; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA; ANGIOGENESIS INHIBITOR; MYC PROTEIN, HUMAN; MYC PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER RISK; CELL DENSITY; CELL STRAIN HCT116; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; EPISTASIS; GENE DELETION; GENE OVEREXPRESSION; GENETIC ENGINEERING; HUMAN; LOSS OF FUNCTION MUTATION; MICROSATELLITE INSTABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; COLORECTAL TUMOR; DRUG EFFECT; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MUTATION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; EPISTASIS, GENETIC; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MUTATION; PROTO-ONCOGENE PROTEINS C-MYC; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84898865217     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju043     Document Type: Article

References (37)

1. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330-337.
2. Dews M, Homayouni A, Yu D, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet. 2006;38(9):1060-1065.
3. Tucker R P. The thrombospondin type 1 repeat superfamily. Int J Biochem Cell Biol. 2004;36(6):969-974.
4. Dews M, Fox JL, Hultine S, et al. The Myc-mir-17~92 axis blunts TGFb signaling and production of multiple TGFb-dependent antiangiogenic factors. Cancer Res. 2010;70(20):8233-8246.
5. Fox JL, Dews M, Minn AJ, Thomas-Tikhonenko A. Targeting of TGFb signature and its essential component CTGF correlates with improved survival in glioblastoma. RNA. 2013;19(2):177-190.
6. Mestdagh P, Bostrom AK, Impens F, et al. The miR-17-92 microRNA cluster regulates multiple components of the TGF-b pathway in neuro-blastoma. Mol Cell. 2010;40(5):762-773.
7. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):l1.
8. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401-404.
9. Miao WM, Seng WL, Duquette M, Lawler P, Laus C, Lawler J. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-b-dependent and-independent mechanisms. Cancer Res. 2001;61(21):7830-7839.
10. Haviv F, Bradley MF, Kalvin DM, et al. Thrombospondin-1 mimetic pep-tide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities. J Med Chem. 2005;48(8):2838- 2846.
11. Valle L, Serena-Acedo T, Liyanarachchi S, et al. Germline allele-specific expression of TGFBR1 confers an increased risk of colorectal cancer. Science. 2008;321(5894):1361-1365.
12. Pasche B, Knobloch TJ, Bian Y, et al. Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA. 2005;294(13):1634-1646.
13. Ijichi H, Ikenoue T, Kato N, et al. Systematic analysis of the TGF-beta-Smad signaling pathway in gastrointestinal cancer cells. Biochem Biophys Res Comm. 2001;289(2):350-357.
14. Stauffer JS, Manzano LA, Balch GC, Merriman RL, Tanzer LR, Moyer M P. Development and characterization of normal colonic epithelial cell lines derived from normal mucosa of patients with colon cancer. Am J Surg. 1995;169(2):190-195.
15. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998;281(5382):1509-1512.
16. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6):904-917.
17. Mertz JA, Conery AR, Bryant BM, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci USA. 2011;108(40):16669- 16674.
18. Koi M, Umar A, Chauhan D P, et al. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res. 1994;54(16):4308-4312.
19. Araki S, Eitel JA, Batuello CN, et al. TGF-b1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer. J Clin Invest. 2010;120(1):290-302.
20. Sundaram P, Hultine S, Smith LM, et al. p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers. Cancer Res. 2011;71(24):7490-7501.
21. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 1995;268(5215):1336-1338.
22. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2013. doi:10.1016/S0140-6736(08)61345-8.
23. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318(5853):1108-1113.
24. Bass AJ, Lawrence MS, Brace LE, et al. Genomic sequencing of colorec-tal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet. 2011;43(10):964-968.
25. Gordon KJ, Blobe GC. Role of transforming growth factor-beta super-family signaling pathways in human disease. Biochim Biophys Acta. 2008;1782(4):197- 228.
26. Bellam N, Pasche B. Tgf-beta signaling alterations and colon cancer. Cancer Treat Res. 2010;155:85-103.
27. Seoane J, Pouponnot C, Staller P, Schader M, Eilers M, Massague J. TGFb influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. Nature Cell Biol. 2001;3(4):400-408.
28. Bierie B, Moses HL. Tumour microenvironment: TGFb: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 2006;6(7):506-520.
29. Simms N, Rajput A, Sharratt EA, et al. Transforming growth factor-b suppresses metastasis in a subset of human colon carcinoma cells. BMC Cancer. 2012;12(1):221.
30. Liu XQ, Rajput A, Geng L, Ongchin M, Chaudhuri A, Wang J. Restoration of transforming growth factor-beta receptor II expression in colon cancer cells with microsatellite instability increases metastatic potential in vivo. J Biol Chem. 2011;286(18):16082-16090.
31. Dong M, How T, Kirkbride KC, et al. The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest. 2007;117(1):206-217.
32. Pepper MS. Transforming growth factor-beta: vasculogenesis, angiogen-esis, and vessel wall integrity. Cytokine Growth Factor Rev. 1997;8(1):21-43.
33. Lonning S, Mannick J, McPherson JM. Antibody targeting of TGF-beta in cancer patients. Curr Pharm Biotechnol. 2011;12(12):2176-2189.
34. van Meeteren LA, Goumans MJ, Ten DP. TGF-beta receptor signaling pathways in angiogenesis; emerging targets for anti-angiogenesis therapy. Curr Pharm Biotechnol. 2011;12(12):2108-2120.
35. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011;10(6):417-27.
36. Dawson MA, Prinjha RK, Dittmann A, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011;478(7370):529-533.
37. Campbell N, Greenaway J, Henkin J, Petrik J. ABT-898 induces tumor regression and prolongs survival in a mouse model of epithelial ovarian cancer. Mol Cancer Ther. 2011;10(10):1876-1885.